Phase 2b ACCESS Study of Aleniglipron in Adults with Obesity or Overweight , published in Press release (Structure Therapeutics) (Structure Therapeutics investigators, 2025): ACCESS II Exploratory Study of Higher-Dose Aleniglipron , published in Press release (Structure Therapeutics) (Structure Therapeutics investigators, 2025): We summarize new studies, safety updates, and dosing insights delivered biweekly
Al-Arfaj, A
Designed for Active Individuals*
Li H, Liu C, Li R, Zhou L, Ran Y, Yang Q, et al
Biological evaluation of these lipopeptides showed no improvement in half-life compared to the natural Peptide5, but did exhibit improved functional efficacy where short lipid chains were used
S., Blagojevic-Bucknall, M., Burton, C., Dziedzic, K